NASDAQ:TELO | Cash Flow Statement | Telomir Pharmaceuticals, Inc.

Complete source-backed cash-flow history.

Available history
2022-12-31 to 2026-06-30
Data captured

Historical Cash Flow Statement

DateNet incomeDepreciation and amortizationOperating cash flowCapital expenditureInvesting cash flowShare repurchasesDividends paidFinancing cash flow
2026-06-30-$1.72M
2026-03-31-$990,947.00-$1.77M$47,351.00
2025-12-31-$2.06M-$1.2M$1.16M
2025-09-30-$1.1M
2025-06-30-$5.07M
2025-03-31-$2.18M-$863,132.00
2024-12-31-$2.9M-$605,808.00$1.04M
2024-09-30-$5.99M
2024-06-30-$1.39M
2024-03-31-$6.25M-$1.94M$5.21M
2023-12-31-$9.33M-$1.09M$1.09M
2023-09-30-$1.71M
2023-06-30-$1.55M
2023-03-31-$482,938.00-$735,739.00$736,127.00

Annual Cash Flow Statement

DateNet incomeDepreciation and amortizationOperating cash flowCapital expenditureInvesting cash flowShare repurchasesDividends paidFinancing cash flow
2025-12-31-$10.41M-$3.69M$9.71M
2024-12-31-$16.53M-$5.07M$6.34M
2023-12-31-$13.07M-$3.86M$3.86M
2022-12-31-$854,147.00-$468,661.00$470,080.00

Research interface only. Not investment advice. Prices are a checked-in snapshot, not live quotes.